Vascular Biogenics Ltd

3:30 PM - 3:45 PM, Tuesday, June 4, 2019 ・ Theater 2
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, VB-111, is a first-in-class, targeted anti-cancer gene-therapy biologic with broad potential to treat a wide range of solid tumors.
Ticker:
VBLT
Exchange:
NASDAQ
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Israel
Year Founded:
2000
Main Therapeutic Focus:
Lead Product in Development:
VB-111
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3
Speaker
photo
CEO
Vascular Biogenics Ltd